Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: An expert agreement

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1896-1907

  Porta, C ^a   Tortora, G ^b   Linassier, C ^c   Papazisis, K ^d   Awada, A ^e   Berthold, D ^f   Maroto, J P ^g   Powles, T ^h   De Santis, M ⁱ  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITÉ DE TOURS   (France)

^d THEAGENIO CANCER HOSPITAL   (Greece)

^e JULES BORDET INSTITUTE   (Belgium)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

ⁱ LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Bevacizumab; Everolimus; Pazopanib; RCC; Renal cell carcinoma; Sequence; Sorafenib; Sunitinib; Temsirolimus; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; LINIFANIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL PRACTICE; COMPARATIVE STUDY; CROSS RESISTANCE; DECISION MAKING; DISEASE CONTROL; DISEASE DURATION; HUMAN; KIDNEY METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS;

EID: 84871517868     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0016-8     Document Type: Review

References (64)

1. Escudier B, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312-8.
2. Escudier B, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28: 2144-50.
3. Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-81.
4. Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
5. Motzer RJ, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-65.
6. Rini BI, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137-43.
7. Sternberg CN, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2010;28:1061-8.
8. Gerullis H, et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol. 2010;27:373-8.
9. Mackenzie MJ, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol. 2011;22:145-8.
10. Merseburger AS, Simon A, Waalkes S, Kuczyk MA. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2009;9:1429-34.
11. Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur J Clin Med Oncol. 2010;4.
12. Rini BI, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4462-8.
13. Porta C, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011. (E-pub ahead of print).
14. NCT00678392: Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ ct2/show/NCT00678392. Accessed 2011.
15. NCT00502307: A study of tivozanib (AV-951), an oral VEGF receptor tyrosine kinase inhibitor, in the treatment of renal cell carcinoma. ClinicalTrials.gov. Available at http://clinicaltrials. gov/ct2/show/ NCT00502307. Accessed 2011.
16. NCT01223027: Study of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma. ClinicalTrials.gov. Available at http://clinicaltrials. gov/ct2/show/NCT01223027. Accessed 2011.
17. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010;36: 16-23.
18. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992-1000.
19. Powles T, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer. 2011;104:741-5.
20. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist. 2010;15: 236-45.
21. Hammers HJ, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9:1525-35.
22. Mier JW. Acquired resistance to VEGF receptor blockade: underlying mechanism and therapeutic options. ASCO 2009 Genitourinary Cancers Symposium, 26-28 February 2009, Orlando, USA; 2009. Available at http://www.asco.org/ ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm-session-presentations- view&confID=64&trackID=40&sessionID= 2855.
23. Di Lorenzo G, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469-74.
24. Garcia JA, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116:5383-90.
25. Mancuso AP, et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J Clin Oncol. 2009;27:abstr e16027.
26. Sepulveda J, et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts. J Clin Oncol. 2008;26(15):abstract 16100.
27. Buchler T, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Ann Oncol. 2011;(E-pub ahead of print).
28. Choueiri TK, et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2008;19:viii191 (abstract 593P).
29. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-7.
30. Eichelberg C, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008;54:1373-8.
31. Richter S, Pfister D, Thur D, Engelmann UH, Heindenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie. 2008;31(4):234 (abstract V684).
32. Sablin MP, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
33. Tamaskar I, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81-6.
34. Zimmermann K, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009;76:350-4.
35. Heuer R, Eichelberg C, Zacharias M, Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib. Eur Urol. 2009;8:183 (abstract 251).
36. Wang S-T, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Eur J Cancer Suppl. 2009;7:436 (abstract 7413).
37. Paez-Ribes M, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
38. NCT00732914: Sequential study to treat renal cell carcinoma. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00732914. Accessed 2011.
39. Tannir NM, et al. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol. 2010;28(15):abstract 4527.
40. Hainsworth JD, et al. A phase II trial of pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab. Ann Oncol. 2010;21(8):vii285 (abstract 910P).
41. NCT00920816: Axitinib (AG-013736) for the treatment of metastatic renal cell cancer. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/ show/NCT00920816. Accessed 2011.
42. NCT01076010: An extension treatment protocol for subjects who have participated in a Phase 3 study of tivozanib versus sorafenib in renal cell carcinoma (protocol AV-951-09-301). ClinicalTrials. gov. Available at http://clinicaltrials.gov/ct2/show/NCT01076010. Accessed 2011.
43. Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-56.
44. Hutson T, Negrier S, Kay A. Randomized, placebo-controlled, phase 3 study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma: subgroup analysis of patients progressing on prior bevacizumab therapy. Eur J Cancer Suppl. 2009;7:434 (abstract P-7136).
45. Schwandt A, et al. Temsirolimus in metastatic RCC: safety and efficacy in patients previously treated with VEGF-targeted therapy. J Clin Oncol. 2009;27(15):abstract 5116.
46. Wood L, Bukowski RM, Dreicer R et al. Temsirolimus in metastatic RCC: safety and efficacy in patients previously treated with VEGF-targeted therapy. ASCO Genitourinary Cancers Symposium 2008. http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=54&abstractID=20313.
47. Vickers MM, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76:430-4.
48. Heng DY, et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol. 2011;29(7):abstract 305.
49. Nozawa M, Matsumura N, Yasuda M, Okuda Y, Uemura H. Activity of retreatment with sorafenib for metastatic renal cell carcinoma. J Clin Oncol. 2011;29(7):abstract 404.
50. Zama IN, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116:5400-6.
51. Dalgliesh GL, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360-3.
52. Herrmann E, et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol. 2011;29:361-6.
53. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323-8.
54. Plaza-Menacho I, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007;282:29230-40.
55. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
56. Kumar R, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101: 1717-23.
57. Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 2008;17:741-8.
58. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010;36:416-24.
59. Elfiky AA, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2010;(Epub ahead of print).
60. Kontovinis L, et al. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol. 2011;(E-pub ahead of print).
61. NCT00903175: Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3). ClinicalTrials.gov. Available at http://clinicaltrials. gov/ct2/show/NCT00903175. Accessed 2011.
62. NCT00474786: Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00474786. Accessed 2011.
63. NCT01064310: Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01064310. Accessed 2011.
64. NCT01217931: Sequential two-agent assessment in renal cell carcinoma therapy. ClinicalTrials.gov. Available at http://clinical trials.gov/ct2/show/ NCT01217931. Accessed 2011.